Amphastar Pharmaceuticals, Inc. income statement

In fiscal 2025, Amphastar Pharmaceuticals, Inc. reported revenue of $720m, down 1.7% on the year before, operating income of $140m (a 19.5% margin) and net income of $98.1m, or $2.03 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Amphastar Pharmaceuticals, Inc.: income statement, annual
Fiscal year	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	204	230	210	252	255	240	295	322	350	438	499	644	732	720	730
Cost of revenue	114	143	159	174	151	150	188	190	207	238	250	293	358	364	382
Gross profit	90	87	51	77	104	91	107	132	143	200	249	351	374	356	348
Research and development	31	33	29	37	42	44	58	69	67	61	75	74	74	86	95
Selling and marketing	4	5	6	5	5	6	8	13	15	17	22	29	38	44	47
General and administrative	27	31	35	42	42	44	50	50	50	51	45	52	57	86	92
Operating income	25	17	−18	−7	15	−1	−9	−0	11	70	107	197	205	140	114
Interest expense	1	1	1	1	1	1	0	0	0	1	2	27	30	25	26
Income before tax	26	17	−18	−10	15	1	−10	60	5	84	116	171	190	124	102
Income tax	8	5	−7	−8	5	−2	−3	14	4	21	23	32	30	26	23
Net income	18	12	−11	−3	10	4	−6	49	1	62	91	138	160	98	79
Diluted EPS	$0.46	$0.31	−$0.25	−$0.06	$0.21	$0.08	−$0.12	$0.98	$0.03	$1.25	$1.74	$2.60	$3.06	$2.03	$1.69
Diluted shares (average)	39m	39m	42m	45m	48m	48m	46m	50m	49m	50m	52m	53m	52m	48m	46m
EBITDA	35	29	−5	4	28	5	−3	7	20	80	120	223	234	172	140

US$ millions unless shown otherwise. Fiscal quarters.

Amphastar Pharmaceuticals, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	191	187	171	174	192	183	171	184
Cost of revenue	89	100	85	88	93	97	101	90
Gross profit	102	87	85	86	99	86	70	93
Research and development	21	18	20	20	22	23	27	22
Selling and marketing	9	10	12	10	12	10	12	13
General and administrative	15	13	16	14	39	16	18	18
Operating income	57	45	37	42	25	36	14	40
Interest expense	7	6	6	6	6	7	7	7
Income before tax	48	44	31	39	22	32	10	39
Income tax	7	6	6	8	4	7	4	8
Net income	40	38	25	31	17	24	6	30
Diluted EPS	$0.78	$0.74	$0.51	$0.64	$0.37	$0.51	$0.14	$0.67
EBITDA	70	34	45	57	39	25	22	54

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AMPH vs PCRX AMPH vs TVTX AMPH vs EBS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Amphastar Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amphastar Pharmaceuticals, Inc.